Dana Devine

Devine received her PhD in immunology from Duke University in 1986.[6][7] She previously completed a bachelor's degree in biology and a master's degree in marine biology, both at Boston University.[8]

Devine first joined Canadian Blood Services (CBS) in 1999, following its creation as a result of the Krever Inquiry, as the executive director of research and development.[8] She was vice-president of medical, scientific, and research affairs for 11 years before becoming Chief Scientist.[9] Her work at CBS has included improvements to testing for transfusion transmitted infection and improvements to platelet unit manufacturing processes.[9] Also in response to the Krever Inquiry, Devine co-founded the Centre for Blood Research in 2002.[10] In 2021, she became its director.[11] Devine was elected president of AABB in 2020, to take office in October 2021.[2][9] She was previously a vice-president of AABB.[12]

For her "critical scientific leadership to Canada’s blood system," Devine was elected a fellow of the Canadian Academy of Health Sciences in 2015.[5]

Devine has been a professor in the University of British Columbia's Department of Pathology and Laboratory Medicine since 2000, where she is also the Graduate Studies Program Director.[13]

Devine's research specialties are in blood system management and quality improvement,[2] platelet biology and coagulation, and complement biochemistry.[8] She is an executive member of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative, where her projects focus on improving the processing, quality, and utilization of conventional blood components.[14][15] Her laboratory at the University of British Columbia is focused on improving the storage quality of platelet units.[8] Devine is also involved in research on the use of convalescent plasma to treat COVID-19,[16] as well as research using Raman spectroscopy to assess the quality of stored red blood cells.[17][18]